Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Congestion, SGLT2 inhibitors and novel therapies Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by